tetano
Editor, Senior Moderator
Brief Bioinform
. 2021 Jan 11;bbaa387.
doi: 10.1093/bib/bbaa387. Online ahead of print.
Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus
Shasha Li[SUP] 1 [/SUP], Wenli Liu[SUP] 1 [/SUP], Yangzhen Chen[SUP] 2 [/SUP], Liqin Wang[SUP] 2 [/SUP], Wenlin An[SUP] 1 [/SUP], Xiaoping An[SUP] 1 [/SUP], Lihua Song[SUP] 1 [/SUP], Yigang Tong[SUP] 1 [/SUP], Huahao Fan[SUP] 1 [/SUP], Chenyang Lu[SUP] 3 [/SUP]
Affiliations
Abstract
Antiviral therapies targeting the pandemic coronavirus disease 2019 (COVID-19) are urgently required. We studied an already-approved botanical drug cepharanthine (CEP) in a cell culture model of GX_P2V, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related virus. RNA-sequencing results showed the virus perturbed the expression of multiple genes including those associated with cellular stress responses such as endoplasmic reticulum (ER) stress and heat shock factor 1 (HSF1)-mediated heat shock response, of which heat shock response-related genes and pathways were at the core. CEP was potent to reverse most dysregulated genes and pathways in infected cells including ER stress/unfolded protein response and HSF1-mediated heat shock response. Additionally, single-cell transcriptomes also confirmed that genes of cellular stress responses and autophagy pathways were enriched in several peripheral blood mononuclear cells populations from COVID-19 patients. In summary, this study uncovered the transcriptome of a SARS-CoV-2-related coronavirus infection model and anti-viral activities of CEP, providing evidence for CEP as a promising therapeutic option for SARS-CoV-2 infection.
Keywords: COVID-19; GX_P2V; SARS-CoV-2; cellular stress; cepharanthine; transcriptome.
. 2021 Jan 11;bbaa387.
doi: 10.1093/bib/bbaa387. Online ahead of print.
Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus
Shasha Li[SUP] 1 [/SUP], Wenli Liu[SUP] 1 [/SUP], Yangzhen Chen[SUP] 2 [/SUP], Liqin Wang[SUP] 2 [/SUP], Wenlin An[SUP] 1 [/SUP], Xiaoping An[SUP] 1 [/SUP], Lihua Song[SUP] 1 [/SUP], Yigang Tong[SUP] 1 [/SUP], Huahao Fan[SUP] 1 [/SUP], Chenyang Lu[SUP] 3 [/SUP]
Affiliations
- PMID: 33423067
- DOI: 10.1093/bib/bbaa387
Abstract
Antiviral therapies targeting the pandemic coronavirus disease 2019 (COVID-19) are urgently required. We studied an already-approved botanical drug cepharanthine (CEP) in a cell culture model of GX_P2V, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related virus. RNA-sequencing results showed the virus perturbed the expression of multiple genes including those associated with cellular stress responses such as endoplasmic reticulum (ER) stress and heat shock factor 1 (HSF1)-mediated heat shock response, of which heat shock response-related genes and pathways were at the core. CEP was potent to reverse most dysregulated genes and pathways in infected cells including ER stress/unfolded protein response and HSF1-mediated heat shock response. Additionally, single-cell transcriptomes also confirmed that genes of cellular stress responses and autophagy pathways were enriched in several peripheral blood mononuclear cells populations from COVID-19 patients. In summary, this study uncovered the transcriptome of a SARS-CoV-2-related coronavirus infection model and anti-viral activities of CEP, providing evidence for CEP as a promising therapeutic option for SARS-CoV-2 infection.
Keywords: COVID-19; GX_P2V; SARS-CoV-2; cellular stress; cepharanthine; transcriptome.